VistaGen Therapeutics (NASDAQ:VTGN) announced the US Patent and Trademark Office issued a patent for “certain methods” on the production of AV-101.
As quoted in the press release:

“The issuance of this U.S. patent by the USPTO advances our intellectual property strategy for AV-101 at this vital period in its clinical development. This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential,” stated Shawn Singh, Chief Executive Officer of VistaGen.

Click here to read the full press release.

Source: www.marketwired.com